This is consistent with clinical evidence showing that IL‐6 blockade improved airflow limitation in COPD patients[60] and preclinical data demonstrating that IL‐17A knockdown mitigated inflammatory lung injury.[61]. Here, IL17A is linked to chronic obstructive pulmonary disease.